A comparison of the MOS-HIV and SF-12v2 for measuring health-related quality of life of men and women living with HIV/AIDS

详细信息    查看全文

• 作者：Allyson Ion (1)
  Wenjie Cai (1)
  Dawn Elston (2)
  Eleanor Pullenayegum (3)
  Fiona Smaill (2)
  Marek Smieja (2) (3) (4)
  
• 刊名：AIDS Research and Therapy
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：8
• 期：1
• 全文大小：228KB
• 参考文献：1. Patrick DL, Erickson P: / Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University Press; 1993.
  2. Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ: A Comparative Review of Health-Related Quality-of-Life Measures for Use in HIV/AIDS Clinical Trials. / Pharmacoeconomics 2006, 24:751-65. CrossRef
  3. Shahriar J, Delate T, Hays RD, Coons SJ: Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. / Health and Quality of Life Outcomes 2003, 1:25. CrossRef
  4. Wu AW, Hays RD, Kelly S, Malitz KF, Bozzette SA: Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. / Qual Life Res 1997, 6:531-54. CrossRef
  5. Wu AW, Revicki DA, Jacobson D, Malitz FE: Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). / Qual Life Res 1997, 6:481-93. CrossRef
  6. Revicki DA, Sorensen A, Wu AW: Reliability and Validity of Physical and Mental Health Summary Scores from the Medical Outcomes Study HIV Health Survey. / Medical Care 1998, 36:126-37. CrossRef
  7. Ware JE, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey. / Medical Care 1996, 34:220-33. CrossRef
  8. Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, Friedland G for the Terry Beirn Community Programs for Clinical Research on AIDS: Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. / AIDS Care 2005, 17:10-2. CrossRef
  9. Han C, Pulling CC, Telke SE, Hullsiek KH for the Terry Beirn Community Programs for Clinical Research on AIDS: Assessing the utility of five domains in SF-12 Health Status Questionnaire in an AIDS clinical trial. / AIDS 2002, 16:431-39. CrossRef
  10. Campbell DT, Fiske DW: Convergent and Discriminant Validation by the Multitrait-Multimethod Matrix. / Psych Bulletin 1959, 56:81-05. CrossRef
  11. John OP, Benet-Martinez V: Measurement: Reliability, construct validation, and scale construction. [http://en.wikipedia.org/wiki/Discriminant_validity] In / Handbook of research methods in social psychology Edited by: Reis HT & Judd CM. New York: Cambridge University Press; 2000, 339-69.
  12. Kinnear TC, Taylor JR: / Marketing Research: An Applied Approach. 3rd edition. Singapore: McGraw-Hill Book Company; 1987.
  13. Litwin MS: / How to Measure Survey Reliability and Validity. London: Sage; 1995.
  14. Fleiss JL, Cohen J: The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. / Educational Psychological Measurement 1973, 33:613-19. CrossRef
  15. Cyr L, Francis K: Measurement of Clinical Agreement for Categorical Data: Kappa Coefficients (PC software. 1992.
  16. Meade MO, Cook RJ, Guyatt GH, Groll R, Kachura JR, Bedard M, Cook DJ, Slutsky AS, Stewart TE: Interobserver Variation in Interpreting Chest Radiographs for the Diagnosis of Acute Respiratory Distress Syndrome. / Am J Respir Crit Care Med 2000, 161:85-0.
  17. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescent. [http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf] Department of Health and Human Services; 2008, 1-39.
  18. Burgoyne RW, Tan DHS: Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. / J Antimicrobial Chemo 2008, 61:469-73. CrossRef
  19. Gill C, Griffith JL, Jacobson D, Skinner S, Gorbach SL, Wilson IB: Relationship of HIV Viral Loads, CD4 Counts, and HAART Use to Health-Related Quality of Life. / JAIDS 2002, 30:485-92. CrossRef
  20. Korthuis PT, Zephyrin LC, Fleishman JA, Saha S, Josephs JS, McGrath MM, Hellinger J, Gebo KA: Health-related quality of life in HIV-infected patients: the role of substance use. / AIDS Patient Care STDs 2008, 22:859-67. CrossRef
  21. Weinfurt KP, Willke RJ, Glick HA, Freimuth WW, Schulman KA: Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. / Medical Care 2000, 38:404-10. CrossRef
  22. Miners AH, Sabin CA, Mocroft A, Youle M, Fisher M, Johnson M: Health-Related Quality of Life in Individuals Infected with HIV in the Era of HAART. / HIV Clin Trials 2001, 2:484-92. CrossRef
  23. Bucciardini R, Fragola V, Massella M, Polizzi C, Mirra M, Goodall R, Carey D, Hudson F, Zajdenverg R, Floridia M: Health-related quality of life outcomes in HIV-infected patients starting different combinations regimens in a randomized multinational trial: the INITIO-QoL substudy. In / AIDS Research and Human Retroviruses. / Volume 23. Initio Trial International Coordinating Committee; 2007:1215-222.
  24. Casado A, Badia X, Consiglio E, Ferrer E, Gonzalez A, Pedrol E, Gatell JM, Azuaje C, Llibre JM, Aranda M, Barrufet P, Martinez-Lacasa J, Podzamczer D and the COMBINE Study Team: Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the Combine-QoL Substudy). / HIV Clin Trials 2004, 5:132-39. CrossRef
  25. Casado A, Consiglio E, Podzamczer D, Badia X: Highly active antiretroviral treatment (HAART) and health-related quality of life in naive and pretreated HIV-infected patients. / HIV Clin Trials 2001, 2:477-83. CrossRef
  26. Revicki DA, Moyle G, Stellbrink HJ, Barker C, PISCES Study Group: Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. / AIDS 1999, 13:851-58. CrossRef
  27. Stangl AL, Wamai N, Mermin J, Awor AC, Bunnell RE: Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda. / AIDS Care 2007, 19:626-36. CrossRef
  28. van Leth F, Conway B, Laplume H, Martin D, Fisher M, Jelaska A, Wit FW, Lange JMA for the 2NN Study Group: Quality of life in patients treated with first-line antiretroviral therapy containing and/or efavirenz. / Antiviral Therapy 2004, 9:721-28.
  
• 作者单位：Allyson Ion (1)
  Wenjie Cai (1)
  Dawn Elston (2)
  Eleanor Pullenayegum (3)
  Fiona Smaill (2)
  Marek Smieja (2) (3) (4)
  
  1. Health Research Methodology Program, Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
  2. Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
  3. Department of Clinical Epidemiology & Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
  4. St. Joseph’s Healthcare, Hamilton, Ontario, Canada
  
• ISSN：1742-6405

文摘

Background The purpose of this study was to examine the relationship between the Medical Outcomes Study-HIV Health Survey (MOS-HIV) and the SF-12v2 to determine if the latter is adequate to assess the health-related quality of life (HRQoL) of men and women living with HIV/AIDS. 112 men and women living with HIV/AIDS who access care at a tertiary HIV clinic in Hamilton, Ontario were included in this cross-sectional analysis. Correlation coefficients of the MOS-HIV physical and mental health summary scores (PHS and MHS) and the SF-12v2 physical and mental component summary scales (PCS and MCS) were calculated along with common sub-domains of the measures including physical functioning (PF), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF) and mental health (MH) to explore the relationship between these two HRQoL measures. The sub-domains role physical (RP) and role emotional (RE) of the SF-12v2 were compared separately to the sub-domain role functioning (RF) of the MOS-HIV. Weighted kappa scores were calculated to determine agreement beyond chance between the MOS-HIV and SF-12v2 in assigning a HRQoL state (i.e. low, moderate, good, very good). Results The MOS-HIV had mean PHS and MHS summary scores of 47.3 (SD = 11.5) and 49.2 (SD = 10.7) respectively. The mean SF-12v2 PCS and MCS scores were 47.7 (SD = 11.0) and 44.0 (SD = 10.4). The MOS-HIV and SF-12v2 physical and mental health summary scores were positively correlated (r = 0.84, p < 0.001 and r = 0.76, p < 0.001). All common sub-domains were significantly correlated at p values from < 0.001 to 0.034. Substantial agreement was observed in assigning a HRQoL state (Physical: κ = 0.788, SE = 0.095; Mental: κ = 0.707, SE = 0.095). Conclusions This analysis validates the SF-12v2 for measuring HRQoL in adult men and women living with HIV/AIDS.